Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.32 |
| ▸ | RXRA | P19793 | 2/20 | 0.32 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | IGF1R | P08069 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | LTK | P29376 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4000170 | 0.79 | GABRA1 (0.42) | KMT2ANPC1RAB9AGABRA1GABRB2 | |
| SCHEMBL7556444 | 0.76 | GABRA1 (0.48) | KMT2ANPC1RAB9AGABRA1GABRB2 | |
| SCHEMBL9397812 | 0.76 | GABRA1 (0.35) | GABRA1GABRB2POLB | |
| SCHEMBL7037293 | 0.76 | GABRA1 (0.38) | KMT2ANPC1RAB9AGABRA1GABRB2 | |
| SCHEMBL19166888 | 0.75 | MAPT (0.46) | KMT2ANPC1RAB9AMAPTLMNA | |
| SCHEMBL9859732 | 0.75 | GABRA1 (0.37) | KMT2ANPC1RAB9AGABRA1GABRB2 | |
| SCHEMBL16487343 | 0.74 | GABRA1 (0.39) | KMT2AGABRA1GABRB2MAPTLMNA | |
| SCHEMBL28175070 | 0.74 | GABRA1 (0.35) | GABRA1GABRB2MAPTLMNAHTT | |
| SCHEMBL27806692 | 0.72 | GABRA1 (0.50) | KMT2AGABRA1GABRB2MAPTRXRA | |
| SCHEMBL5403133 | 0.72 | GABRA1 (0.40) | KMT2ANPC1RAB9AGABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10568851-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-02-25 | — | — | US | claimed |
| US-20140235562-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2014-08-21 | — | — | US | claimed |
| US-20140235604-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-08-21 | — | — | US | claimed |
| WO-2013063269-A2 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-05-02 | — | — | WO | claimed |
| US-20120295895-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-11-22 | — | — | US | claimed |
| EP-2509596-A2 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | Case Western Reserve University (US) | 2012-10-17 | — | — | EP | claimed |
| WO-2011071995-A2 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2011-06-16 | — | — | WO | claimed |
| US-20070027212-A1 | ALPHA 2 DELTA LIGANDS FOR FIBROMYALGIA AND OTHER DISORDERS | PFIZER INC | 2007-02-01 | — | — | US | claimed |
| US-7164034-B2 | Alpha2delta ligands for fibromyalgia and other disorders | PFIZER INC. (US) | 2007-01-16 | — | — | US | claimed |
| EP-1572188-A1 | PREGABALIN DERIVATIVES FOR THE TREATMENT OF FIBROMYALGIA AND OTHER DISORDERS | Warner-Lambert Company LLC (US) | 2005-09-14 | — | — | EP | claimed |
| EP-1515709-A2 | USE OF AN ALPHA2DELTA LIGAND SUCH AS GABAPENTIN OR PREGABALIN FOR TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER | Warner-Lambert Company LLC (US) | 2005-03-23 | — | — | EP | claimed |
| EP-1469841-A1 | ALPHA 2 DELTA LIGANDS TO TREAT TINNITUS | WARNER-LAMBERT COMPANY (US) | 2004-10-27 | — | — | EP | claimed |
| US-20040186177-A1 | Alpha2delta ligands for fibromyalgia and other disorders | DOOLEY DAVID JAMES (US) | 2004-09-23 | — | — | US | claimed |
| WO-2004054566-A1 | PREGABALIN DERIVATIVES FOR THE TREATMENT OF FIBROMYALGIA AND OTHER DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-01 | — | — | WO | claimed |
| US-20040097405-A1 | Method of treating cartilage damage | SCHRIER DENIS (US) | 2004-05-20 | — | — | US | claimed |
| WO-2004002462-A2 | USE OF AN ALPHA2DELTA LIGAND SUCH AS GABAPENTIN OR PREGABALIN FOR TREATING TTENTION DEFICIT HYPERACTIVITY DISORDER | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-08 | — | — | WO | claimed |
| US-20040006073-A1 | Method of treating attention deficit hyperactivity disorder | DOOLEY DAVID JAMES (US) | 2004-01-08 | — | — | US | claimed |
| US-20030176504-A1 | Method of treating tinnitus | DOOLEY DAVID JAMES (US) | 2003-09-18 | — | — | US | claimed |
| WO-2003063845-A1 | ALPHA 2 DELTA LIGANDS TO TREAT TINNITUS | WARNER-LAMBERT COMPANY LLC (US) | 2003-08-07 | — | — | WO | claimed |
| EP-1199072-A2 | Method of treating cartilage damage | WARNER-LAMBERT COMPANY (US) | 2002-04-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235562-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, TXNRD2, TXNRD1 | KMT2A 4342/4885NPC1 333/4885RAB9A 554/4885 |
| US-20030176504-A1 | Method of treating tinnitus | ADRA2A, ADRA1A, ADRA1D | KMT2A 823/4885NPC1 905/4885RAB9A 2119/4885 |
| US-20070027212-A1 | ALPHA 2 DELTA LIGANDS FOR FIBROMYALGIA AND OTHER DISORDERS | OPRD1, HCRTR2, OPRL1 | KMT2A 1829/4885NPC1 1661/4885RAB9A 1461/4885 |
| US-20120295895-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, NR2E3, LRAT | KMT2A 2643/4885NPC1 29/4885RAB9A 432/4885 |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, TXNRD2, TXNRD1 | KMT2A 4342/4885NPC1 333/4885RAB9A 554/4885 |
| US-20040186177-A1 | Alpha2delta ligands for fibromyalgia and other disorders | OPRD1, HTR1A, HTR3A | KMT2A 854/4885NPC1 1633/4885RAB9A 1032/4885 |
| US-20040097405-A1 | Method of treating cartilage damage | COL2A1, COL1A1, GABRB1 | KMT2A 3421/4885NPC1 1649/4885RAB9A 2855/4885 |
| US-20140235604-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, NR2E3, LRAT | KMT2A 2643/4885NPC1 29/4885RAB9A 432/4885 |
| US-20040006073-A1 | Method of treating attention deficit hyperactivity disorder | GABRB2, GABBR1, GABBR2 | KMT2A 1176/4885NPC1 1081/4885RAB9A 1639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.